{"id":"novocart-inject-plus","safety":{"commonSideEffects":[{"rate":null,"effect":"Joint swelling"},{"rate":null,"effect":"Joint pain"},{"rate":null,"effect":"Effusion"},{"rate":null,"effect":"Infection at injection site"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of autologous (patient-derived) chondrocytes suspended in a fibrin matrix that is injected directly into articular cartilage lesions. The chondrocytes integrate into the defect site and produce extracellular matrix components, promoting repair and regeneration of damaged hyaline cartilage. This approach aims to restore cartilage structure and function while reducing pain and improving joint mobility.","oneSentence":"NOVOCART® Inject plus is an autologous chondrocyte implantation therapy that delivers cultured patient cartilage cells directly into cartilage defects to promote tissue regeneration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:24.281Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Symptomatic articular cartilage defects of the knee"}]},"trialDetails":[{"nctId":"NCT03319797","phase":"PHASE3","title":"NOVOCART® Inject Plus for Cartilage Defects of the Knee","status":"COMPLETED","sponsor":"Tetec AG","startDate":"2017-10-10","conditions":"Cartilage Defects of the Knee","enrollment":100},{"nctId":"NCT02179346","phase":"","title":"Observational Study With NOVOCART® Inject in the Reconstruction of the Hip Joint With Full Thickness Cartilage Defects","status":"COMPLETED","sponsor":"Tetec AG","startDate":"2014-12","conditions":"Cartilage Disease","enrollment":21},{"nctId":"NCT02941120","phase":"","title":"Non-interventional Study With NOVOCART® Inject in the Reconstruction of the Knee Cartilage Defects","status":"COMPLETED","sponsor":"Tetec AG","startDate":"2015-12","conditions":"Cartilage Disease","enrollment":245}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NOVOCART® Inject plus","genericName":"NOVOCART® Inject plus","companyName":"Tetec AG","companyId":"tetec-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NOVOCART® Inject plus is an autologous chondrocyte implantation therapy that delivers cultured patient cartilage cells directly into cartilage defects to promote tissue regeneration. Used for Symptomatic articular cartilage defects of the knee.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}